The partnership aims to increase trial efficiency, expand patient access to therapies, and support new discoveries.

ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...

On June 22, 2026, the U.S. Department of Health and Human Services (HHS) announced the launch of Operation TrialBlazer, a coordinated effort ...

Broad consensus about need for disclosure and clinician oversight ...

New capability lets sponsors run programs from early rodent proof-of-concept through advanced nonhuman-primate translational studies with a single AAALAC-accredited, USDA-licensed partner. YEMASSEE, ...

New capability lets sponsors run programs from early rodent proof-of-concept through advanced nonhuman-primate translational studies with a single AAALAC-accredited, USDA-licensed partner. YEMASSEE, S ...

MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable ...

Roche to present new data from its Alzheimer’s disease portfolio at AAIC 2026 in London on 12-15 July: Basel Wednesday, July 8, 2026, 12:00 Hrs [IST] Roche announced that it wil ...

The University of West Attica bestowed Kon Mouzakis with the title of Honorary Professor, recognising the distinguished ...

(DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated ...

GeneCentric, a precision medicine company bringing gene expression biology to liquid biopsy, today announced the launch of ExpressCT Rewind™, a retrospective fragmentomics analysis service that ...

Volume 21, Issue 2 highlights the technologies, workflows and clinical insights helping dentists improve efficiency, predictability and patient care. IRVINE, CA / ACCESS Newswire / July 8, 2026 / ...